Mesa Laboratories (MLAB) Posts Earnings Results, Beats Estimates By $0.24 EPS

Mesa Laboratories (NASDAQ:MLAB) released its quarterly earnings data on Tuesday. The medical instruments supplier reported $1.08 EPS for the quarter, beating analysts’ consensus estimates of $0.84 by $0.24, Bloomberg Earnings reports. Mesa Laboratories had a positive return on equity of 9.20% and a negative net margin of 3.82%.

Mesa Laboratories opened at $192.99 on Wednesday, MarketBeat Ratings reports. The company has a market cap of $633.94 million, a P/E ratio of 71.31 and a beta of 0.47. The company has a current ratio of 2.37, a quick ratio of 1.64 and a debt-to-equity ratio of 0.58. Mesa Laboratories has a 52-week low of $122.35 and a 52-week high of $202.00.

The company also recently declared a quarterly dividend, which will be paid on Friday, June 15th. Investors of record on Thursday, May 31st will be paid a dividend of $0.16 per share. The ex-dividend date is Wednesday, May 30th. This represents a $0.64 dividend on an annualized basis and a yield of 0.33%. Mesa Laboratories’s dividend payout ratio is presently 15.17%.

In related news, Director Robert V. Dwyer sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 14th. The stock was sold at an average price of $144.01, for a total transaction of $720,050.00. Following the transaction, the director now owns 68,521 shares in the company, valued at approximately $9,867,709.21. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 15.70% of the company’s stock.

MLAB has been the topic of a number of recent analyst reports. BidaskClub upgraded Mesa Laboratories from a “sell” rating to a “hold” rating in a report on Wednesday, February 7th. TheStreet downgraded Mesa Laboratories from a “b-” rating to a “c” rating in a research note on Wednesday, February 7th. Zacks Investment Research downgraded Mesa Laboratories from a “hold” rating to a “sell” rating in a research note on Saturday, February 10th. Finally, ValuEngine upgraded Mesa Laboratories from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd.

About Mesa Laboratories

Mesa Laboratories, Inc designs, manufactures, and markets quality control instruments and disposable products. The company's Instruments segment offers data loggers, which are precision instruments used in critical manufacturing, quality control, and validation applications; medical meters and calibration solutions used to test various parameters of the dialysis fluid, and the calibration and operation of the dialysis machine; gas flow calibration and air sampling equipment that are used for industrial hygiene assessments, calibration of gas metering equipment, and environmental air monitoring; and torque testing systems used for measure bottle cap tightness.

Earnings History for Mesa Laboratories (NASDAQ:MLAB)

Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply